Placebo News and Research

RSS

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Sucampo Pharmaceuticals, Inc. and Abbott today reported data from a phase 3 clinical efficacy trial in 124 Japanese chronic idiopathic constipation patients as well as from a phase 3 long-term safety trial in an additional 209 Japanese CIC patients.

10 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

Expert says Homeopathy is 'ethically unacceptable'

A bioethics expert from the University of Abertay Dundee has denounced the public funding of homeopathy at a time where Scotland's health budget is under unprecedented pressure.

9 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Diamyd Medical announces European Phase III study results in type 1 diabetes

Diamyd Medical reports that results from its European Phase III study with the antigen-based therapy Diamyd did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients.

9 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

7 May 2011

Neutralizing antibodies generated by immunization associated with protection against SIV infection

Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). The researchers found that neutralizing antibodies generated by immunization were associated with protection against SIV infection.

6 May 2011

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration approved Afinitor tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.

6 May 2011

New drugs need to provide more data on how they compare with existing ones: Study

According to US researchers, data on drugs that could save money and help doctors make smarter treatment decisions are often unavailable at the time new medicines hit the market. They released a study this Tuesday in Journal of the American Medical Association which found nearly a third of new drug approvals from the Food and Drug Administration included no data on how well the medications compare with existing alternatives.

5 May 2011

Asthma ‘pill-a-day’ shows similar effectiveness as inhalers: Study

A new study has shown that a ‘once-a-day’ pill may be on par with an inhaler at combating asthma. This tablet, say researchers could revolutionize treatment for the condition, meaning patients are no longer reliant on inhalers, which many find difficult to use. Around 5.4 million Britons have asthma, including 1.1 million children.

5 May 2011

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Pfizer Inc. announced that Revatio (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.

5 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2011.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Placebo News and Research

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Expert says Homeopathy is 'ethically unacceptable'

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Diamyd Medical announces European Phase III study results in type 1 diabetes

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

Neutralizing antibodies generated by immunization associated with protection against SIV infection

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

New drugs need to provide more data on how they compare with existing ones: Study

Asthma ‘pill-a-day’ shows similar effectiveness as inhalers: Study

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Acorda reports $0.7 million GAAP net loss for first quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

Columbia Laboratories net revenues increase 74% to $12.5 million

Clinical study: Celecoxib drug may treat breast cancer

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News